Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Complete title: A Phase 1/2 STudy Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Research Study Number 20170627
Principal Investigator John Thompson, MD
Phase I/II

Research Study Description

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "LOOK UP TRIAL AT NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20170627
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Breast Cancer; Cervical Cancer; Endometrial Cancer; Gastric Cancer; Head and Neck Cancer; Lung Cancer; Melanoma; Mesothelioma; Ovarian Cancer; Rectal Cancer; Solid Tumors; Lung Carcinoma, Non-Small-Cell (NSCLC); Carcinoma, Squamous Cell; Colorectal Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Hepatocellular; Triple Negative Breast Neoplasms; Lung Carcinoma, Small-Cell; Urothelial Cancer; Advanced Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials